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Abstract
Background: This naturalistic open label follow-up study had three objectives:
1) To observe the course of illness in Panic Disorder patients receiving long-term versus
intermediate-term paroxetine treatment
2) To compare the relapse rates and side-effect profile after long-term paroxetine treatment
between patients with Panic Disorder and Panic Disorder with Agoraphobia.
3) To observe paroxetine's tolerability over a 24 month period.
Methods:  143 patients with panic disorder (PD), with or without agoraphobia, successfully
finished a short-term (ie 12 week) trial of paroxetine treatment. All patients then continued to
receive paroxetine maintenance therapy for a total of 12 months. At the end of this period, 72 of
the patients chose to discontinue paroxetine pharmacotherapy and agreed to be monitored
throughout a one year discontinuation follow-up phase. The remaining 71 patients continued on
paroxetine for an additional 12 months and then were monitored, as in the first group, for another
year while medication-free. The primary limitation of our study is that the subgroups of patients
receiving 12 versus 24 months of maintenance paroxetine therapy were selected according to
individual patient preference and therefore were not assigned in a randomized manner.
Results: Only 21 of 143 patients (14%) relapsed during the one year medication discontinuation
follow-up phase. There were no significant differences in relapse rates between the patients who
received intermediate-term (up to 12 months) paroxetine and those who chose the long-term
course (24 month paroxetine treatment). 43 patients (30.1%) reported sexual dysfunction. The
patients exhibited an average weight gain of 5.06 kg. All patients who eventually relapsed
demonstrated significantly greater weight increase (7.3 kg) during the treatment phase.
Conclusions: The extension of paroxetine maintenance treatment from 12 to 24 months did not
seem to further decrease the risk of relapse after medication discontinuation. Twenty-four month
paroxetine treatment is accompanied by sexual side effects and weight gain similar to those
observed in twelve month treatment.
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Background
Panic Disorder (PD) is considered to be a chronic debili-
tating illness, which is characterized by recurrent, severe
and apparently spontaneous anxiety attacks accompanied
by autonomic symptoms [1]. This disorder constitutes a
major health problem with significant costs not only for
the individual but for the health service system as well [2].
PD has an estimated lifetime prevalence of about 3–5%
[1]. The most common therapeutic interventions are Cog-
nitive Behavioral Therapy [3] and pharmacotherapy [4,5].
Pharmacological treatments for PD have centered mainly
on benzodiazepines and antidepressants [4,6,7]. Benzodi-
azepines have shown to be effective with rapid onset of
action [8]. The long-term use of benzodiazepines, how-
ever, may be associated with the development of physio-
logical dependence and withdrawal symptoms [2].
Studies with tricyclic agents and monoamine oxidase
inhibitors (MAOIs) [9,10] have demonstrated good effi-
cacy in the treatment of PD. Selective sertonin reuptake
inhibitors (SSRIs), however, are better tolerated than the
older agents with fewer side-effects and so have become
the treatment of choice for PD [11]. Numerous controlled
studies have demonstrated the effectiveness of these drugs
[12-14].
Paroxetine was the first SSRI approved for treatment of PD
[15], and its efficacy is well established in the short-term
treatment of patients with PD [16,17]. According to the
current APA practice guidelines for the treatment of PD, it
is recommended to continue SSRI pharmacotherapy for
one year despite a paucity of data examining the compar-
ative efficacy of long-term (>12 months) treatment [11].
The optimal continuation period of paroxetine treatment
to prevent future relapse is unclear.
Paroxetine treatment involves relatively high cost to the
patients and to the health services. Long-term paroxetine
treatment is associated with adverse effects such as sexual
dysfunction and weight gain [5]. Lately, two studies have
reported that adverse effects on sexual function occur in
up to 75% of patients treated with paroxetine [6,18].
In this naturalistically designed follow-up study we
address the following questions:
1) Does long term paroxetine treatment for up to 24
months will prevent relapse more effectively than twelve
months of treatment?
2) What is the course of PD versus PD with agoraphobia?
3) What is the prevalence of sexual dysfunction and
weight gain in long-term paroxetine treatment?
Methods
Patients
Over one hundred and eighty patients passing diagnostic
screening for a diagnosis of PD or PDA were entered into
a short-term (12 week) treatment phase in which they
received paroxetine pharmacotherapy. 143 patients (78
women and 65 men; average age = 39.2 ± 9.2) showed an
improvement in panic symptoms after the short-term
treatment phase and entered a one year maintenance
phase. All patients who entered the maintenance phase
met the DSM-IV criteria for PD (n = 85) or PDA (n = 58).
17 patients had a history of prior drug or alcohol abuse.
Exclusion criteria included the presence of a comorbid
axis I diagnosis, long-term benzodiazepine use (>12
months), current substance abuse, and prior non-
response to paroxetine therapy. Patients were generally
physically healthy, although our patient sample included
11 patients with cardiovascular disease, 4 patients with
hypertension, and 4 patients with non-insulin dependent
diabetes mellitus. Twenty-seven (19%) of the patients had
family history of anxiety disorders. 70% of our patients
developed the onset of panic disorder between ages 20–
40 and the remainder between ages 41–75. The majority
of patients in our study (68%) were referred to us after a
first episode of panic disorder.
Study design
This naturalistic outcome study was conducted at Sheba
Medical Center in Israel. The participants were referred to
the hospital's psychiatry ward either by an ER physician or
by a family physician. All patients gave their informed
consent for participating in the study. After an initial eval-
uation that included a semi-structured psychiatric inter-
view and Panic Self Questionnaire (PSQ), all patients
received paroxetine at an initial starting dose of 10 mg/
day for one week and then 20 mg/day for one month.
After one month of 20 mg/day paroxetine therapy, the
dose was either maintained at 20 mg/day or increased to
40 mg/day according to individual patient response. 67/
143 responders received adjunctive benzodiazepine ther-
apy with either clonazepam (n = 42) or lorazepam (n =
25) during the first eight to twelve weeks of treatment.
Note that clonazepam was given at a dose of 0.5–1.5 mg/
day and lorazepam was given at a dose of 1–3 mg/day.
After approximately 8–9 weeks of adjunctive benzodi-
azepine therapy, the benzodiazepines were gradually
tapered and discontinued over a three week period. After
week 12 of the study, none of our study patients contin-
ued to receive adjunctive benzodiazepine therapy. Note
that the primary care physician of each patient was con-
tacted to explain that the patients should not receive
adjunctive benzodiazepines during the maintenance
phase and medication discontinuation follow-up phase
of the study. By week 12 of the study, all 143 respondersBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/16
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entered into the one year maintenance phase in which
they received paroxetine monotherapy.
After one year of paroxetine maintenance therapy, 127/
143 (89%) patients were considered full responders, and
16/143 patients had a partial response to treatment (1–2
panic attacks per week). Full response was defined as com-
plete absence of panic attacks including the absence of
limited symptom attacks. At this point all of the patients
were offered the choice of either: 1) medication taper and
discontinuation or 2) continuing paroxetine pharmaco-
therapy for an additional year. An equal possibility to
taper medication was offered to all patients. A subgroup
of 72 full responders elected to taper and discontinue
medication treatment. These patients remained under
psychiatric supervision and were monitored in either the
out-patient clinic or through telephone calls every two
months, for a period of 6–12 months (average of 11
months). The evaluations made at the last clinical visit of
each patient were regarded as the patient's final assess-
ment. The remaining 71 patients (including 55 full
responders and 16 partial responders) elected to continue
paroxetine treatment for an additional year. After this
additional period, these patients were also tapered off par-
oxetine and were followed medication-free for one year
with clinical visits or telephone calls bimonthly.
Assessments of relapse and side-effects
Evaluations of the patient's condition were conducted at
baseline and every 2 months, until the end of the study,
and were based on the Panic Self-Questionnaire (PSQ)
[19]. Relapse was defined as the occurrence of at least one
panic attack after discontinuation of paroxetine
treatment.
In accordance with previous studies, we monitored
[1,3,20] weight gain and sexual dysfunction, for these are
considered to be the most bothersome side effects of sub-
acute and long-term paroxetine treatment. All patients
were weighed at baseline before starting paroxetine ther-
apy and then again at the end of maintenance therapy.
Weight change was calculated by subtracting the weight at
the baseline visit from the weight at their last clinical visit.
Sexual disturbances were assessed clinically, in both men
and women, with questions exploring sexual desire and
sexual dysfunction. We note that a structured interview
regarding sexual symptoms was not used.
Statistics
Statistical analysis was performed with t-test and ANOVA
and ANOVA with repeated measures and χ2. Levels of sig-
nificance were set to .05 unless otherwise stated.
Results
Demographic and baseline versus endpoint measure-
ments are summarized in tables 1, 2
Relapse
We defined relapse as the occurrence of a single panic
attack after discontinuation of pharmacotherapy. 21/127
patients (17%) who entered the maintenance phase expe-
rienced one or more panic attacks during the one year fol-
low-up period after paroxetine discontinuation. In the
intermediate-term treatment group (12 months), the
number of patients experiencing relapse was 13/72 (18%)
as opposed to 8/55 (15%) in the long-term treatment
group (24 months). The difference in relapse rates
between the intermediate and long-term treatment groups
was not statistically significant (df 1; χ2 = 3.78; P > 0.05).
There were no significant differences in relapse rate
between patients according to age, gender, or presence of
Table 1: Demographics and baseline measurements (N:143)*
Intermediate treatment Long term treatment p
X ± SD X ± SD
(N = 72) (N = 71)
Age (y) 38.7 ± 9.6 39.6 + 8.9 NS
Gender (F/M) 39/33 41/30 NS
Age group (≤50, >50) 62/10 61/10 NS
Diagnosis (PD/PD and Agoraphobia) 48/24 37/34 NS
Past history of drug/alcohol abuse 12 5 NS
Comorbid physical problems 5 6 NS
Weight (baseline) 66.9 ± 8.8 65.2 ± 7.9 NS
PSQ (Number of panic attacks/w) 5.9 ± 1.4 6.2 ± 1.4 NS
* Explanation: intermediate = 12 months long-term => 12 monthsBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/16
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agoraphobia. The relapse rate of both the patients with
drug and/or alcohol abuse did not differ from the rest
(NS). Among the 67 patients who received benzodi-
azepines in addition to the paroxetine treatment, 13
(20%) relapsed, and the increased relapse rate in this
group was statistically significant. (df 1; χ2 = 4.74; P <
0.05).
Common side effects
Weight gain
Body weight among the study population increased by
5.06 ± 3.66 kg from a mean weight of 66.1 ± 8.4 kg at the
onset of treatment. This increase was statistically signifi-
cant (t = -16.54; CI = -5.67, -4.46; P < 0.01). The relapsing
patients gained significantly more weight (7.3 ± 6.9) than
the fully recovered (4.9 ± 3.3) (t = 2.203; CI = -4.75, 0; P
< 0.05). Weight gain was significantly greater among the
patients who received benzodiazepines (t = 3.07; CI = -
3.79, 0.80; P < 0.01) and among those over age 50 (t =
2.29; CI = 0.27, 3.71; P < 0.05).
No significant difference in the amount of weight gain
was observed between the patients who completed 12
months of paroxetine treatment and the patients who
continued the medication for more than 12 months.
There were no significant differences in weight gain
between patients according to gender, the use of drugs/
alcohol, or the presence of agoraphobia.
Sexual side-effects
43 out of the 143 patients (30%) reported sexual impair-
ment. The prevalence of sexual side effects did not differ
between the patients who completed 12 months of parox-
etine treatment (29%) and the patients who received par-
oxetine for more than 12 months (33%) (df 1, χ2 = 0.56,
P > 0.05). Sexual side effects did not differ significantly
according to gender, age, or past history of drug and/or
alcohol use (NS). However, sexual side effects were sub-
stantially more common in patients who suffered from
PD with agoraphobia (41%) than in patients who suf-
fered from PD (22%) (df 1, χ2 = 5.93, P < 0.02).
PD versus PD with agoraphobia
Patients suffering from PD with agoraphobia had more
attacks per week at the onset time of treatment (6.5+1.4)
in comparison to the PD without agoraphobia patients
(5.8+1.3) (t = 3.00; CI = -1.13, -0.23 ; P < 0.05).
In addition, 36/58 patients suffering from PD with agora-
phobia (62.1%) required benzodiazepine augmentation
compared with 31/85 (36.5%) among the patients with
PD alone (df 1; χ2 = 9.07; P < 0.05).
Discussion
We report that paroxetine is effective for both Panic Dis-
order (PD) and Panic Disorder with Agoraphobia (PGA).
In our patient sample, the diagnosis of PDA was associ-
ated with more panic attacks per week than the diagnosis
of PD alone. Our study shows that for both patients with
PD and PDA, the relapse rate is the same whether the
patient receives maintenance therapy for one or two years.
Continuing paroxetine for an additional 12 months had
no significant effect on relapse rates. This is one of the first
studies to examine the effectiveness of long–term (up to
24 month) paroxetine therapy in preventing relapse in
panic disorder.
The results of our study showed that paroxetine is highly
efficacious in the short-term and intermediate-term treat-
ment of PD and PDA, and this is consistent with the
results of numerous efficacy studies [21-23]. The high effi-
cacy rate of paroxetine pharmacotherapy also closely
reflects the high response rates seen with Cognitive Behav-
ioral Therapy [3]. Interestingly, our relapse rate of 15–
18% after medication discontinuation parallels the 15%
relapse rate reported by Park et al during a two year
follow-up after 14 weeks of successful behavioral therapy
for PD [24]. Our relapse rate of 15–18% during the one
year discontinuation follow-up phase, however, is lower
than reported in another medication discontinuation
study. Mavissakalian et al in a small, prospective study
examined PDA patients who received imipramine (IMI)
for a second year of maintenance therapy and then were
followed for 6 months after medication discontinuation
Table 2: Assessments at the end of maintenance therapy
Intermediate treatment Long-term treatment t CI X2 p
N = 72 N = 55
Relapse* 13 (18%) 8 (15%) NS
Weight gain 4.7 ± 3.9 5.2 ± 3.4 NS
Sexual dysfunction 21 (29%) 18 (33%) NS
PSQ (Number of panic attacks/w)* 0.22 ± 0.7 0.23 ± 0.2 NS
*assessment made at the end of one year follow-up after medication discontinuationBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/16
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[20]. The results of this study showed a relapse rate of up
to 37%. Also, results of the IMI study showed that a sec-
ond year of treatment was associated with improved out-
come in terms of relapse prevention. We hypothesize that
the differences in the study design may account for the
lower relapse rate seen in our study. It is possible that par-
oxetine therapy is superior to IMI therapy in terms of
relapse prevention. Alternatively, a selection effect may
account for the relatively better outcome of our study
patients after paroxetine discontinuation. Our patients
did not have comorbid axis I disorders, and it is possible
that the lack of comorbid diagnoses lowers the risk of
relapse.
In our study, we were able to examine the side effects of
paroxetine over a 24 month period. We observed that sex-
ual side-effects were reported by 30% of the patients who
received maintenance therapy. This finding is consistent
with previous studies which demonstrated that up to 75%
of the patients who receive paroxetine report sexual dys-
function [25-27].
We found that paroxetine pharmacotherapy produced a
similar weight gain in both the 12 and 24 month mainte-
nance therapy subgroups. From this finding, we postulate
that weight gain related to paroxetine occurs mainly dur-
ing the first 12 months of treatment. Interestingly, we
observed that weight gain in both the intermediate and
long-term treatment groups was positively correlated with
risk of relapse. It is possible that a greater increase in body
weight could lead to an increased risk of panic attacks
because of psychobiological effects. Alternatively, the rel-
atively small number of patients who relapsed could
cause a β error therefore biasing our results. Further stud-
ies are needed in order to clarify this issue.
Patients who received adjunctive benzodiazepines during
the initiation of paroxetine therapy had a greater tendency
to relapse following 12 months of paroxetine mainte-
nance treatment. We can assume that the use of adjunctive
benzodiazapines early in treatment is related to a higher
baseline anxiety level. This finding suggests, therefore,
that a higher level of anxiety at the start of treatment is
associated with a greater risk of future relapse. Further
research is needed in order to examine the possibility that
higher baseline anxiety levels may represent a risk factor
for later relapse. It is possible that close psychiatric follow-
up after termination of maintenance pharmacotherapy
may be especially indicated for these patients. Patients
treated with benzodiazepine augmentation therapy also
showed a tendency to gain more weight. Further studies
are needed in order to address the question of whether
patients suffering from higher baseline anxiety levels may
be at increased risk for weight gain with paroxetine
treatment.
Our study results indicate that being agoraphobic poten-
tiates the sexual side effects induced by paroxetine in
patients with panic disorder. It is not clear why the agora-
phobic patients tended to report more sexual side effects
with paroxetine treatment. Perhaps for psychodynamic
reasons, agoraphobic patients are more likely to suffer
from sexual dysfunction and are therefore more sensitive
to medication induced sexual side effects. Alternatively,
we cannot rule out the possibility that our cohort of ago-
raphobic patients suffered from an increased level of sex-
ual dysfunction at baseline and therefore selection bias
may represent a confounding variable in our results. The
higher level of anxiety seen in agoraphobic patients may
predispose them to have an increased tendency for
somatic complaints including higher rates of sexual
dysfunction.
The primary strength of this preliminary study is that it is
a real life outcome study whose longitudinal design
closely reflects actual clinical practice. In addition, the rel-
Table 3: Comparison of Panic Disorder versus Panic Disorder with Agoraphobia
PD PD and AGORAPHOBIA df X2 p
(N = 85) (N = 58)
X ± SD X ± SD
Age 38.6 ± 1 40.0 ± 8 NS
Gender (F/M) 45/40 33/25 NS
Age group (≤50, >50) 73/12 50/8 NS
Relapse 14% 19% NS
Weight gain 5.6 ± 3.3 5.4 ± 3.7 NS
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atively large sample size and the high retention rate
strengthen our results. The major limitations of our study
include the use of non-blinded raters, the lack of a pla-
cebo control group, and the non-randomization of the
two subsamples of patients treated for 12 and 24 months.
Without the use of a placebo control group, we cannot
rule out the possibility that the raters were unintention-
ally biased to see positive results (in both the mainte-
nance and discontinuation phases) in all patients. A
randomized, double-blind study is needed in order to
confirm our findings.
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